- MEI Pharma Inc (NASDAQ:MEIP) and Infinity Pharmaceuticals Inc (NASDAQ:INFI) have entered into a definitive merger agreement for an all-stock transaction forming a company focusing on three clinical-stage oncology drug candidates.
- Infinity's Eganelisib is planned to be evaluated in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in patients with head and neck squamous cell carcinoma (HNSCC).
- Related: Infinity Pharma Posts 52% Increase In One-Year Progression-Free Survival Rate In Breast Cancer Patients.
- MEI Pharma's Voruciclib is currently being studied with AbbVie Inc's (NYSE: ABBV) Venclexta (venetoclax) for hematologic malignancies.
- MEI Pharma's ME-344 will be evaluated with Roche Holdings AG's (OTC: RHHBY) Avastin (bevacizumab) for relapsed colorectal cancer.
- Related: MEI Pharma, Kyowa Kirin Cull Development Of Blood Cancer Drug Outside Japan, Look For Strategic Alternatives.
- Infinity will become a wholly-owned subsidiary of MEI Pharma.
- MEI Pharma shareholders are expected to own approximately 58.0%, and pre-merger Infinity shareholders are expected to own approximately 42.0% of the outstanding equity of the combined company immediately following the merger.
- The merger is expected to close in mid-2023.
- Projected ~$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months.
- Price Action: MEIP shares are down 15.30% at $0.25, and INFI shares are down 45.50% at $0.30 on the last check Thursday.
Loading...
Loading...
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
